KRAS and neoplasm: The KRAS mutations lead to constant activation of KRAS and persistent stimulation of its downstream signaling pathways that drive many of the hallmarks of cancer, sustained proliferation, metabolic reprogramming, antiapoptosis, remodeling of the tumor microenvironment, evasion of the immune response, cell migration, and metastasis (45).